|
WO2020254552A2
|
|
Substituted pyrrolidine amides v
|
|
WO2020254551A1
|
|
Substituted pyrrolidine amides iv
|
|
AU2020100442A4
|
|
Dosage form providing prolonged release of tapentadol phosphoric acid salt
|
|
AU2020202055A1
|
|
Dosage form providing prolonged release of tapentadol phosphoric acid salt
|
|
AU2020202056A1
|
|
Dosage form providing prolonged release of tapentadol phosphoric acid salt
|
|
AU2020100441A4
|
|
Dosage form providing prolonged release of tapentadol phosphoric acid salt
|
|
TW202043211A
|
|
Substituted pyrrolidine amides iii
|
|
US2020030317A1
|
|
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
|
EP3789378A1
|
|
Piperidines or piperidones substituted with urea and heteroaryl
|
|
WO2020030777A1
|
|
Composition for treating urinary frequency and/or urinary urgency
|
|
WO2020030597A1
|
|
Method for carrying out structured rehabilitation
|
|
AU2019304532A1
|
|
Substituted triazolo quinoxaline derivatives
|
|
TW202007687A
|
|
Further substituted triazolo quinoxaline derivatives
|
|
US2019274974A1
|
|
Treatment of Pain Associated with Trigeminal Neuralgia
|
|
JP2019142972A
|
|
Parenteral administration of tapentadol
|
|
WO2019170904A1
|
|
Piperidines or piperidones substituted with urea and phenyl
|
|
EP3698776A1
|
|
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
|
TW202002957A
|
|
Tamper resistant formulation of ephedrine and its derivatives comprising a conversion inhibitor
|
|
AU2018387793A1
|
|
Substituted pyrrolidine amides I
|
|
US2019111050A1
|
|
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
